Trial Profile
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2022
Price :
$35
*
At a glance
- Drugs Relmacabtagene-autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2022 Two years results of a phase 1 trial assessing 2-year efficacy and safety of relma-cel in Chinese patients with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL) published in the Bone Marrow Transplantation
- 07 Jun 2022 Results of updated 2-year survival data analysis presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2022 According to a JW Therapeutics media release, results from this study presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,